Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7803270 | 0.83 | NOS3 (0.41) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL20689253 | 0.79 | NOS3 (0.39) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL24131411 | 0.79 | HSP90AA1 (0.37) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL5038676 | 0.77 | ALDH1A1 (0.44) | IDO1KMT2ACYP3A4CYP2C19TSHR | |
| SCHEMBL30816293 | 0.77 | NOS3 (0.50) | NOS3NOS1NOS2HSP90AA1CYP3A4 | |
| SCHEMBL130124 | 0.77 | NOS3 (0.50) | NOS3NOS1NOS2HSP90AA1CYP3A4 | |
| SCHEMBL20686331 | 0.76 | NOS3 (0.36) | NOS3NOS1NOS2HSP90AA1HSP90AB1 | |
| SCHEMBL18668145 | 0.75 | HSD11B1 (0.39) | HSP90AA1TRPV1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL24858173 | 0.75 | CA2 (0.41) | KMT2ACYP3A4CYP2C19TSHRGRM4 | |
| SCHEMBL23126660 | 0.75 | ACSS2 (0.36) | TRPV1CYP3A4CYP2C19TSHRGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-11583529-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDEYRA THERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20150209345-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-07-30 | — | — | US | disclosed |
| US-20150209333-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-07-30 | — | — | US | disclosed |
| US-8940764-B2 | Compositions and methods of treating retinal disease | ALDEXA THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940721-B2 | Compositions and methods of treating retinal disease | ALDEXA THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20110263645-A1 | Compositions and Methods of Treating Retinal Disease | NEURON SYSTEMS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7973025-B2 | Compositions and methods of treating retinal disease | NEURON SYSTEMS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100160304-A1 | AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20090182009-A1 | Compositions and methods of treating retinal disease | NEURON SYSTEMS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| EP-1844768-A1 | AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20070135481-A1 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209345-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDH1A2, CLN6, PLA2G2E | NOS3 1235/4885NOS1 2152/4885NOS2 1249/4885 |
| US-20090182009-A1 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | NOS3 1312/4885NOS1 2156/4885NOS2 1279/4885 |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | NOS3 1312/4885NOS1 2156/4885NOS2 1279/4885 |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | NOS3 296/4885NOS1 571/4885NOS2 261/4885 |
| US-11583529-B2 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | NOS3 296/4885NOS1 571/4885NOS2 261/4885 |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDH2, CLN6, ALDH1A1 | NOS3 1207/4885NOS1 1274/4885NOS2 1131/4885 |
| US-20150209333-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDH1A2, PLA2G2E, CLN6 | NOS3 1312/4885NOS1 2156/4885NOS2 1279/4885 |
| US-20100160304-A1 | AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR | NR3C2, AGTR1, AGTR2 | NOS3 442/4885NOS1 880/4885NOS2 1398/4885 |
| US-20070135481-A1 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | NOS3 1312/4885NOS1 2156/4885NOS2 1279/4885 |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | NOS3 296/4885NOS1 571/4885NOS2 261/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | NOS3 4412/4885NOS1 4483/4885NOS2 4218/4885 |
| US-20110263645-A1 | Compositions and Methods of Treating Retinal Disease | ALDH1A2, CLN6, PLA2G2E | NOS3 1235/4885NOS1 2152/4885NOS2 1249/4885 |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | NOS3 4525/4885NOS1 4691/4885NOS2 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.